TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02624349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadravalent human papillomavirus vaccine
Description: Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadravalent human papillomavirus vaccine
Description: Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
Study: NCT01251692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
Study: NCT02600273

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand cigarettes
Description: Usual brand cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower nicotine content cigarettes
Description: SPECTRUM research cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes 1
Description: Electronic cigarette with 0 g/mL e-liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes 2
Description: Electronic cigarette with 18 g/mL e-liquid
Study: NCT02959554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
Study: NCT02136797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMVpp65 Specific T-cells
Study: NCT01810328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traumatized population
Description: In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Volunteers
Description: The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
Study: NCT02585752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Expiratory pressure modulation
Study: NCT03310372

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated brain irradiation
Description: 0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
Study: NCT00841945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: RITUXIMAB 375 MG/M² IV DAY 1 or each course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: RITUXIMAB 375 MG/M² IV DAY 1 or each course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: doxorubicin 50 mg / m² iv day 1 of each course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: doxorubicin 50 mg / m² iv day 1 of each course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: VINCRISTINE 1?4 MG/M² IV ON DAY 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: VINCRISTINE 1?4 MG/M² IV ON DAY 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone 40 mg/m² DAy 1 to day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone 40 mg/m² DAy 1 to day 5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy : total dose = 40 GY (5 fractions by week)
Study: NCT04221308

Intervention type: DEVICE
Intervention: Single port laparoscopic systems
Description: The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
Study: NCT01179659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study
Study: NCT03965481

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dynamic Enhanced CT
Description: Undergo standard CECT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI scan
Study: NCT00647374

Intervention type: OTHER
Intervention: this is an observational study
Study: NCT01375777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study: NCT05399667

Intervention type: OTHER
Intervention: Early stimulation
Description: Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants

Intervention type: OTHER
Intervention: Conventional care
Description: Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
Study: NCT04888208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
Study: NCT03746886

Intervention type: OTHER
Intervention: Breast-milk
Description: A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
Study: NCT01749033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 Classic
Description: Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 pre-inflated
Description: Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 ELL-PIC
Description: Group 3 (ELL-PIC): Using the ELL-PIC technique
Study: NCT03760926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: May Health Kit
Description: The intervention consists in the realisation of the May Health Procedure using the May Health Kit, which comprises two elements: a disposable device (May Health Device) and a radiofrequency (RF) energy generator (May Health System). The May Health Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
Study: NCT03294447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall Prevention by the Occupational Therapist
Description: The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
Study: NCT02917109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LearningRx cognitive training
Description: A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
Study: NCT00745927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CO2 insufflations
Description: CO2 insufflations during whole procedure of colonoscopy
Study: NCT04461522

Intervention type: PROCEDURE
Intervention: Ultrasound-guided drug injection
Description: The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
Study: NCT02715765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Sham Stimulation
Description: Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
Study: NCT02356016

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS Intervention
Description: Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS-Intervention and dietary supplementation
Description: Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control (dietary counseling)
Description: Monthly dietary counseling only
Study: NCT01990443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab IV
Description: Reslizumab 220-mg intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab SC
Description: Reslizumab 220 mg administered subcutaneous (SC)
Study: NCT02331134

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
Study: NCT02060890

Intervention type: OTHER
Intervention: specialized tumor board recommendation
Description: feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
Study: NCT02578394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100mg and Placebo Depo-Medrone
Description: Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrone 120mg and Placebo (Anakinra)
Description: Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
Study: NCT03086447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: Senofilcon C Toric

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens
Description: Air Optix for Astigmatism
Study: NCT01213017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Description: 400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
Study: NCT04211103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Study: NCT00765908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty balloon
Description: 90 second balloon inflation x 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty balloon
Description: 30 seconds or less balloon inflations x 2
Study: NCT03216837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Description: The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
Study: NCT02200822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Study: NCT03701490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone subcutaneous
Description: 25 mg/twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Vaginal Product
Description: 200 mg three times a day.
Study: NCT01359072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self administered coping intervention
Description: The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self administered coping intervention
Description: The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
Study: NCT03405909

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast enhanced ultrasound (CEUS)
Description: CEUS with SonoVue following standardized protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: CE-MRI following standardized protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: diagnostic liver biopsy
Study: NCT02556931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6 through -2: 30 mg/m\^2 IV daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6 through -2: 30 mg/m\^2 IV daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 cGy in a single fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 cGy in a single fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
Study: NCT02532140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 250 mg to 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 250 mg to 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 250 mg to 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 1000/2000 mg with Cefepime 2000 mg combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 1000/2000 mg with Cefepime 2000 mg combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00654446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin